New research presented Monday at the American Society of Clinical Oncology Annual Meeting shows that patients with stage III colon cancer that followed an anti-inflammatory diet extended their overall survival compared with patients who didn’t follow that regimen. The findings , by researchers at Dana-Farber Cancer Institute (DFCI), based their analysis on data from a large phase III clinical trial launched in 2010 with the goal of finding ways to reduce the recurrence of colon cancer.

“One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,” said the study’s first author Sara Char, MD, a clinical fellow in Hematology and Oncology at DFCI. “These findings add to the published li

See Full Page